The Risk of Allergic Reaction to SARS-CoV-2 Vaccines a Management: A Systematic Review, Meta-Analysis, GRA Consensus Approach

Journal of Allergy and Clinical Immunology: in Practice

9, 3546-3567

DOI: 10.1016/j.jaip.2021.06.006

Citation Report

#	Article	IF	Citations
1	Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink. JAMA - Journal of the American Medical Association, 2021, 326, 1375-1377.	7.4	15
2	COVID-19 vaccines and vaccine hesitancy: Role of the allergist/immunologist in promotion of vaccine acceptance. Allergy and Asthma Proceedings, 2021, 42, 386-394.	2.2	17
3	Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing. Annals of Allergy, Asthma and Immunology, 2021, 128, 97-98.	1.0	9
4	COVID-19 vaccines: addressing hesitancy in young people with allergies. Lancet Respiratory Medicine,the, 2021, 9, 1090-1092.	10.7	13
5	Tolerability of polysorbate 80â€“containing COVID-19 vaccines in confirmed polyethylene glycolâ€“allergic patients. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4470-4472.e1.	3.8	13
6	Translating Evidence to Optimize Patient Care Using GRADE. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4221-4230.	3.8	30
7	Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction. Annals of Allergy, Asthma and Immunology, 2022, 128, 217-218.	1.0	3
8	Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccine in Patients with Hypersensitivity to First Dose. Open Forum Infectious Diseases, 2021, 8, ofab507.	0.9	20
9	COVID-19 mRNA vaccine allergy. Current Opinion in Pediatrics, 2021, 33, 610-617.	2.0	15
10	Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination. JAMA Network Open, 2021, 4, e2131034.	5.9	18
11	Serious complications of COVID-19 vaccines: A mini-review. Metabolism Open, 2021, 12, 100145.	2.9	25
12	Occurrence and response to treatment of Gravesâ€™ disease after COVID vaccination in two male patients. Endocrine, 2022, 75, 19-21.	2.3	20
13	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Safety, 2021, 44, 1247-1269.	3.2	85
14	Reacciones adversas asociadas a vacunas contra la COVID-19. CES Medicina, 2021, 35, 230-243.	0.1	2
15	Allergists Can Safely Evaluate and Revaccinate Individuals With Immediate Allergic Reactions to mRNA COVID-19 Vaccines. Open Forum Infectious Diseases, 2022, 9, ofab584.	0.9	2
16	COVIDâ€19 vaccines tolerated in patients with paclitaxel and docetaxel allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1048-1051.	5.7	8
17	Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions. Annals of Allergy, Asthma and Immunology, 2021, , .	1.0	14
18	School Asthma Care During COVID-19: What we have learned, and what we are learning. Journal of Allergy and Clinical Immunology: in Practice, 2021, , .	3.8	1

#	Article	IF	Citations
19	The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVIDâ€19 vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1658-1660.	5.7	22
20	Specialist allergy advice allows vaccination in patients with reactions to COVIDâ€19 vaccines. Clinical and Experimental Allergy, 2022, 52, 465-469.	2.9	2
21	Emergency department visits for vaccine-related severe allergic reactions among US adults: 2006-2018. Annals of Allergy, Asthma and Immunology, 2022, 128, 319-321.	1.0	2
22	Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy and Asthma Proceedings, 2022, 43, 30-36.	2.2	31
23	Reliability of televisits for patients with mild relapsingâ€“remitting multiple sclerosis in the COVID-19 era. Neurological Sciences, 2022, , 1.	1.9	3
24	COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. Allergy and Asthma Proceedings, 2021, 42, 515-521.	2.2	15
25	SARS-CoV-2 vaccine-associated-tinnitus: A review. Annals of Medicine and Surgery, 2022, 75, 103293.	1.1	17
26	The adverse reactions to vaccines practice parameter 10 years on -what have we learned?. Annals of Allergy, Asthma and Immunology, 2022, , .	1.0	8
28	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology, 2022, 149, 569-578.	2.9	3
29	Allergies and COVIDâ€19 vaccines: An ENDA/EAACI Position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2292-2312.	5.7	55
30	Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose. Frontiers in Allergy, 2022, 3, 825164.	2.8	18
31	COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices. Journal of Clinical Epidemiology, 2022, 144, 163-172.	5.0	7
32	The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 630-632.	3.8	11
33	Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 620-625.e1.	3.8	37
34	Allergic reactions to the Ad26.COV2.S vaccine in South Africa. , 2022, 1, 2-8.		3
35	Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine. Journal of Infectious Diseases, 2022, 226, 1231-1236.	4.0	1
36	Graded coronavirus disease 2019 vaccine administration. Annals of Allergy, Asthma and Immunology, 2022, , .	1.0	5
37	Role of Allergist Advice in Determining Personal Decisions for COVID-19 Vaccination of People With a History of Allergies. Cureus, 2022, 14, e23156.	0.5	1

#	Article	IF	Citations
38	Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics. Annals of Allergy, Asthma and Immunology, 2022, 129, 88-94.e1.	1.0	13
39	Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccinationâ€“Associated Hypersensitivity Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 827-836.	3.8	17
40	Hypersensitivity Reactions to COVID-19 Vaccinesâ€”Identify High-risk Children and Vaccinate the Rest. JAMA Pediatrics, 2022, 176, 443.	6.2	6
41	Oncologist counseling practice and COVIDâ€19 vaccination outcomes for patients with history of PEGâ€asparaginase hypersensitivity. Pediatric Blood and Cancer, 2022, , e29686.	1.5	2
42	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Annals of Allergy, Asthma and Immunology, 2022, 129, 40-51.	1.0	14
43	Rapid progress in our understanding of COVID-19 vaccine allergy: AÂcause for optimism, not hesitancy. Journal of Allergy and Clinical Immunology, 2022, 150, 12-16.	2.9	11
44	Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines. JAMA Internal Medicine, 2022, 182, 376.	5.1	66
45	Idiopathic anaphylaxis: Diagnosis and management. Allergy and Asthma Proceedings, 2021, 42, 481-488.	2.2	8
46	COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches. Frontiers in Allergy, 2021, 2, 801322.	2.8	9
47	Applying the Clinical Literature to a Science of Uncertainty and an Art of Probability. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4233-4234.	3.8	1
48	Experience with polyethylene glycol allergyâ€guided risk management for COVIDâ€19 vaccine anaphylaxis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2200-2210.	5.7	34
49	Successful graded-dose challenge of the Janssen vaccine against SARS-CoV-2 in a high-risk patient. QJM - Monthly Journal of the Association of Physicians, 2022, , .	0.5	2
50	COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication. Vaccines, 2022, 10, 718.	4.4	9
51	COVID-19 mRNA vaccine-induced lung injury: A case report. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-5.	0.5	1
52	Adverse Events and Safety of SARS-CoV-2 Vaccines: Whatâ€™s New and Whatâ€™s Next. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2254-2266.	3.8	4
53	Vaccination against COVID-19 Patients with Allergic Diseases. The Position of the Allergologist-Immunologist. Literature review. Epidemiologiya I Vaktsinoprofilaktika, 2022, 21, 91-97.	0.8	0
54	Mucocutaneous Adverse Reactions to COVID-19 Vaccines: Do Excipients Play a Role?. Acta Dermato-Venereologica, 2022, , .	1.3	0
55	Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5â€“11â€‰years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP). Italian Journal of Pediatrics, 2022, 48, 76.	2.6	9

#	Article	IF	Citations
56	Protocol of safe vaccination against COVIDâ€19 in patients with high risk of allergic reactions. Clinical and Translational Allergy, 2022, 12, .	3.2	9
57	Allergic Reactions After the Administration of COVID-19 Vaccines. Frontiers in Public Health, 2022, 10, .	2.7	7
58	Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study. Annals of Allergy, Asthma and Immunology, 2022, 129, 182-188.e1.	1.0	10
60	Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines, 2022, 10, 1260.	3.2	6
61	Allergological study in patients vaccinated against COVID-19 with suspected allergic reactions. Allergy, Asthma and Clinical Immunology, 2022, 18, .	2.0	4
62	Intradermal Testing With COVID-19 mRNA Vaccines Predicts Tolerance. Frontiers in Allergy, 2022, 3, .	2.8	8
63	Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	30
64	Global prevalence and clinical manifestations of cutaneous adverse reactions following COVIDâ€19 vaccination: A systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1947-1968.	2.4	26
65	Adverse Reactions to Anti-Infective Vaccines: an Emerging Problem in the COVID-19 Era. Current Treatment Options in Allergy, 0, , .	2.2	5
66	Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs, 2022, 36, 443-458.	4.6	20
67	We should abandon the Brighton Collaboration criteria for vaccine-associated anaphylaxis. Annals of Allergy, Asthma and Immunology, 2022, 129, 20-21.	1.0	5
68	We should not abandon the Brighton Collaboration criteria for vaccine-associated anaphylaxis. Annals of Allergy, Asthma and Immunology, 2022, 129, 17-19.	1.0	6
69	True, true, and unrelated: Stop routine testing to vaccine excipients for suspected vaccine allergy. Annals of Allergy, Asthma and Immunology, 2022, 129, 24-26.	1.0	2
70	Biologics and anti-Sars Cov2 vaccination in severe asthma riding the big wave: Unity is strength!. Pulmonology, 2022, , .	2.1	0
71	Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1931-1933.	3.8	5
72	Vaccines against <scp>SARSâ€CoV</scp> â€2 are safe to administer in patients with antibodies to pegaspargase. Cancer Medicine, 0, , .	2.8	0
73	Safety outcomes of SARS-CoV-2 vaccination in pediatric patients with a first dose reaction history or allergy to polyethylene glycol or polysorbate. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	0
74	Safe administration of subsequent <scp>mRNA COVID</scp>â€19 vaccine doses following a possible allergic reaction to the first dose. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1

#	Article	IF	Citations
75	New Challenges in Drug Allergy: the Resurgence of Excipients. Current Treatment Options in Allergy, 0, , .	2.2	4
76	Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders. Medicine (United States), 2022, 101, e29571.	1.0	4
77	<scp>Asia Pacific</scp> perspectives on the second year of the <scp>COVID</scp>â€19 pandemic: A followâ€up survey. Clinical and Experimental Allergy, 2022, 52, 965-973.	2.9	8
78	Drug hypersensitivity, in vitro tools, biomarkers, and burden with <scp>COVID</scp>â€19 vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3527-3537.	5.7	2
79	Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks. Expert Review of Vaccines, 2022, 21, 1377-1394.	4.4	8
80	Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy. , 2022, 1, 209-216.		1
81	Value-Based, Cost-Effective Care: The Role of the Allergist-Immunologist. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 132-139.	3.8	6
82	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	1.6	0
83	Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India. Vaccine: X, 2022, 12, 100210.	2.1	2
84	Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 458-465.e1.	3.8	1
85	Distinct Clinical Features of Post-COVID-19 Vaccination Early-onset Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 108, 107-113.	3.6	12
86	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	1.6	0
87	Anaphylaxis: Advances in the Past 10 Years. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 51-62.	3.8	6
88	Allergic diseases and immunodeficiencies in children, lessons learnt from <scp>COVID</scp>â€19 pandemic by 2022: A statement from the <scp>EAACI</scp>â€section on pediatrics. Pediatric Allergy and Immunology, 2022, 33, .	2.6	5
89	A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants. Cureus, 2022, , .	0.5	10
90	Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination. International Archives of Allergy and Immunology, 2023, 184, 54-62.	2.1	1
91	Graded-dosing immunization in adults at risk for immediate-type reactions to mRNA SARS-CoV-2 vaccines. Allergology International, 2023, 72, 332-334.	3.3	1
92	Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10â€“17 Years in Thailand. Vaccines, 2022, 10, 1765.	4.4	10

#	Article	IF	Citations
93	PEG allergy â€" A COVID-19 pandemic-made problem? A German perspective. World Allergy Organization Journal, 2022, 15, 100714.	3.5	7
94	Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. Pathogens, 2022, 11, 1259.	2.8	4
95	Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to <scp>COVID</scp>â€19 vaccines: AÂsystematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 71-83.	5.7	14
96	Risk of Adverse Events of Live-Attenuated COVID-19 Vaccination Among Atopic Patients. Journal of Asthma and Allergy, 0, Volume 15, 1605-1621.	3.4	4
97	Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders. Pathogens, 2022, 11, 1364.	2.8	1
98	Anaphylaxis: Revision of the Brighton collaboration case definition. Vaccine, 2023, 41, 2605-2614.	3.8	15
99	Self-reported allergy to medications containing the same excipients as SARS-CoV2 vaccines: importance of skin testing with excipients. Italian Journal of Dermatology and Venereology, 0, , .	0.2	0
100	Polysorbate 80 blocked a peripheral sodium channel, Na_v1.7, and reduced neuronal excitability. Molecular Pain, 0, , 174480692211501.	2.1	1
101	Safety of mRNA COVID-19 vaccinations in patients with allergic diseases. Public Health in Practice, 2023, 5, 100354.	1.5	0
102	Covid-19 Vaccine Provocation Test Outcome In High-Risk Allergic Patients: A Retrospective Study From A Tertiary Hospital In Indonesia. World Allergy Organization Journal, 2022, , 100734.	3.5	2
103	Recent developments in the immunopathology of <scp>COVID</scp>â€19. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 369-388.	5.7	33
104	Is there value in coronavirus disease 2019 vaccine and vaccine excipient skin testing or split dosing?. Annals of Allergy, Asthma and Immunology, 2022, 129, 667-668.	1.0	1
105	The conundrum of COVID-19 mRNA vaccineâ€"induced anaphylaxis. , 2023, 2, 1-13.		5
106	COVID-19 vaccine allergy advice and guidance: The experience of a UK tertiary referral centre. World Allergy Organization Journal, 2023, 16, 100740.	3.5	1
107	COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review. BMC Infectious Diseases, 2023, 23, .	2.9	2
108	mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation. Current Allergy and Asthma Reports, 2023, 23, 195-200.	5.3	3
109	ATAK Complex (Adrenaline, Takotsubo, Anaphylaxis, and Kounis Hypersensitivity-Associated Coronary) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.4	2
110	Side Effects Associated With Homologous and Heterologous COVID-19 Vaccines: A Cross-Sectional Study in Saudi Arabia. Cureus, 2023, , .	0.5	0

#	Article	IF	Citations
111	Fractionated vaccination with mRNA COVIDâ€19 vaccine is safe for patients with polyethylene glycol allergy. Clinical and Translational Allergy, 2023, 13, .	3.2	1
112	Skin Testing and Basophil Activation Testing Is Useful for Assessing Immediate Reactions to Polyethylene Glycol-Containing Vaccines. Vaccines, 2023, 11, 252.	4.4	2
113	Anaphylaxis: from Bench to Bedside Issue: Current Update on Anaphylaxis. Current Pharmaceutical Design, 2023, 29, 163-164.	1.9	0
115	Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): AÂscoping review. , 2023, 2, 100079.		2
116	Reply to â€œPolyethylene glycol/polysorbate skin testing can be useful in risk assessment and management of allergic/pseudoallergic reactions to nanolipid/adenoviral vaccinesâ€• Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 666-667.	3.8	0
117	Histopathological Patterns of Cutaneous Adverse Reaction to Anti-SARS-CoV-2 Vaccines: The Integrative Role of Skin Biopsy. Vaccines, 2023, 11, 397.	4.4	0
118	Vaccine anaphylaxis and Canadian public health policy. Lancet Respiratory Medicine,the, 2023, 11, 306-308.	10.7	0
119	Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVACâ„¢) among General and High-Risk Population. Vaccines, 2023, 11, 437.	4.4	0
121	Increasing the COVIDâ€19 immunization rate through allergy testing. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1228-1235.	2.4	5
122	Allergic Reactions to Vaccines in Children: From Constituents to Specific Vaccines. Biomedicines, 2023, 11, 620.	3.2	1
123	Localized Delayed T-cell Mediated Hypersensitivity After mRNA SARS-CoV-2 Vaccination. Cureus, 2023, , .	0.5	0
124	National assessment strategy for adults and children with a history of vaccine allergy shows low utility of ‹scp›COVID‹/scp›â€19 vaccine skin testing. Pediatric Allergy and Immunology, 2023, 34, .	2.6	1
125	Pearls for practice from the 2022 joint task force drug allergy practice parameter. Current Opinion in Pediatrics, 0, Publish Ahead of Print, .	2.0	1
126	Provision of Food Allergy Care in the United Kingdom and United States: Current Issues and Future Directions. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 2054-2066.	3.8	3
127	SARS-CoV-2 and allergy â€“ what have we learned after two and a half years?. Allergologie Select, 2023, 7, 101-112.	3.1	5
128	Before and After: Attitude and Adverse Effects Induced by the First and Second Doses of mRNA BNT162b2 Vaccine among Healthcare Professionals in the First Weeks after Their Introduction in Poland. Vaccines, 2023, 11, 883.	4.4	0
130	Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 2008-2022.	3.8	2
131	Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine, 2023, 41, 4183-4189.	3.8	6

#	Article	IF	Citations
133	A practical guide to address reactions to vaccines in children. Pediatric Allergy and Immunology, 2023, 34, .	2.6	0
134	COVID-19 vaccine uptake and hesitancy in Chinese patients with asthma. Journal of Asthma, 0, , 1-10.	1.7	1
135	Potentiating the Cross-Reactive IFN-Î³ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine. International Journal of Molecular Sciences, 2023, 24, 9753.	4.1	0
136	Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: AÂGRADE assessment and international consensus approach. Journal of Allergy and Clinical Immunology, 2023, 152, 309-325.	2.9	4
137	Impact of SARS-CoV-2 Infection in Children with Asthma and Impact of COVID-19 Vaccination: Current Evidence and Review of the Literature. Microorganisms, 2023, 11, 1745.	3.6	3
138	An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 3305-3318.	3.8	6
139	Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis. International Journal of Public Health, 0, 68, .	2.3	2
140	Evaluation of disease control after SARS-CoV-2 infection or vaccination in patients with NSAID-exacerbated airway disease. Allergy and Asthma Proceedings, 2023, 44, e3-e10.	2.2	1
141	COVID-19 Treatments: Then and Now. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 3321-3333.	3.8	1
142	Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study. Journal of Allergy and Clinical Immunology, 2023, , .	2.9	2
143	Reply to â€œThe nature and severity of SARS-CoV-2 vaccines side effects are highly dependent on study designâ€• and â€œSelf-reported side effects following COVID-19 vaccination in athletes: Correspondenceâ€• Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
144	The Long Road of Long COVID: Specific Considerations for the Allergist and Immunologist. Journal of Allergy and Clinical Immunology: in Practice, 2023, , .	3.8	1
145	COVIDâ€19 mRNA vaccine, but not a viral vectorâ€based vaccine, promotes neutralizing antiâ€type I interferon autoantibody production in a small group of healthy individuals. Journal of Medical Virology, 2023, 95, .	5.0	0
146	Gastrointestinal reflux contributes to laryngopharyngeal symptoms that mimic anaphylaxis: COVID-19 vaccination experience. , 2024, 3, 100176.		0
147	RNA vaccines: A milestone toward a new era. Vojnosanitetski Pregled, 2023, 80, 811-813.	0.2	0
148	Cutaneous Reactions to Non-mRNA COVID-19 Vaccines. Updates in Clinical Dermatology, 2023, , 31-40.	0.1	0
149	How does the pandemic shape the future of allergies?. BMJ Nutrition, Prevention and Health, 2023, 6, s2-s7.	3.7	0
150	Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity to Polyethylene Glycolated Escherichia coli L-asparaginase. Journal of Pediatric Hematology/Oncology, 2024, 46, e202-e204.	0.6	0

#	Article	IF	Citations
151	Unsafe medications for patients with food allergy. Singapore Medical Journal, 0, , .	0.6	0
152	Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study. Vaccine, 2024, 42, 1440-1444.	3.8	0